News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Penn Startups Raising Capital – Spring 2022
PCI supports and facilitates startup formation and growth through our startup creation programs and our licensing partnerships. This list of Penn affiliated startups are actively fundraising.
Medical device startup Neuralert has big 2022 plans
The device's algorithm maps out asymmetric arm movements or weakness, a tell-tale sign of a stroke, CEO Eric Corkhill said. Here's why he's so excited about its potential.
USPTO launches new Patent Public Search tool and webpage
The USPTO announced a new Patent Public Search tool that provides more convenient, remote, and robust full-text searching of all U.S. patents and published patent applications.
Decade-long remission after CAR T cell therapy
Two patients represent longest-known CAR T cell response to date, providing insight into treatment effect and outcomes.
It’s official: Philly Tech Week is back and IRL in 2022
The 12th annual celebration of technology, entrepreneurship and innovation will be held May 6 to 14, 2022 with a mix of in-person and virtual events.
Two Penn spinouts on the Technical.ly Philly RealLIST standout tech companies
Of the 20 companies on the Technical.ly Philly RealLIST, two are Penn spinout companies: Lumify and Neuralert.
ExynAI has been shortlisted as a finalist for a SXSW Innovation Award
For the 2022 category of Robotics and Hardware. The Exyn team will be going to Austin for the awards.
Penn’s Gene Therapy Program signs manufacturing partnership with the Center for Breakthrough Medicines
The Center for Breakthrough Medicines and Penn’s Gene Therapy Program (GTP) entered into a multi-year collaboration focusing on the manufacturing and testing of modern gene therapy processes.
The Center for Breakthrough Medicines and Penn partner in the manufacturing of gene therapies
Penn’s Innovation in Process Science combines with CBM manufacturing capability to develop large-scale gene therapy manufacturing capacity, testing, and analytics
Halting Progress and Happy Accidents: How mRNA vaccines were made
A New York Times feature on the history, research, challenges, and timeline to make the COVID-19 mRNA vaccines.